Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Mar 27, 2022; 14(3): 247-259
Published online Mar 27, 2022. doi: 10.4240/wjgs.v14.i3.247
Published online Mar 27, 2022. doi: 10.4240/wjgs.v14.i3.247
Ref. | Total sample | Sex, male/female, n | Age, yr | Symptoms duration, yr or mo | MBI | Classification, n (%) | Pre-ECK scores | LESP, mmHg | IRP, mmHg |
Familiari et al[15], 2016 | LM: 38 | NA | NA | NA | NA | NA | NA | NA | NA |
SM: 35 | |||||||||
Gao et al[16], 2017 | LM: 53 | LM: 29/24; SM: 25/22 | LM: 37.83 ± 14.36 | LM: 5.23 ± 5.87 | LM: 19.76 ± 3.07 | NA | LM: 6.75 ± 1.86 | LM: 43.03 ± 13.73 | NA |
SM: 47 | SM: 43.96 ± 11.69 | SM: 5.30 ± 4.87 | SM: 20.25 ± 2.97 | SM: 6.34 ± 1.74 | SM: 41.93 ± 14.93 | ||||
Gong et al[17], 2016 | LM: 59; SM: 38 | Female; LM: 29; SM: 19 | LM: 39.8 ± 12.4; SM: 41.5 ± 7.2 | LM: 6.5 ± 5.5; SM: 7.9 ± 4.3 | LM: 20.7 ± 2.6; SM: 20.1 ± 3.2 | ASAC I: LM: 47; SM: 29; II: LM: 11; SM: 7; III: LM: 1; SM: 2; CC I: LM: 21; SM: 12 II: LM: 38; SM: 26 | LM: 7.2 ± 2.4; SM: 6.8 ± 1.7 | LM: 42.1 ± 12.9; SM: 44.6 ± 13.2 | NA |
Gu et al[14], 2020 | LM: 48; SM: 46 | LM: 23/25; SM: 21/25 | LM: 42.8 ± 10.2; SM: 43.6 ± 11.4 | LM: 4.1(0.3~31.0); SM: 5.0(0.3~34.0) | NA | CC II: LM: 48; SM: 46 | LM: 7.1 ± 1.6; SM: 7.5 ± 1.5 | LM: 32.4 ± 5.3; SM: 33.5 ± 5.0 | LM: 21.5 ± 4.6; SM: 23.2 ± 4.8 |
Huang et al[13], 2020 | LM: 74; SM: 36 | Female; LM: 34; SM: 17 | LM: 37.7 ± 13.0; SM: 40.8 ± 11.1 | LM: 8.9 ± 5.8; SM: 8.8 ± 5.5 | LM: 19.4 ± 3.1; SM: 20.3 ± 2.6 | ASAC I: LM: 58; SM: 33; II: LM: 15; SM: 2; III: LM: 1; SM: 1; CC I: LM: 26; SM: 12; II: LM: 48; SM: 24 | LM: 7.5 ± 1.9; SM: 7.1 ± 1.6 | LM: 39.8 ± 13.7; SM: 41.8 ± 14.3 | NA |
Nabi et al[12],2020 | LM: 37; SM: 34 | LM: 24/13; SM: 18/16 | LM: 41.3 ± 14.4; SM: 40.1 ± 16.8 | LM: 3;SM: 3 | NA | ASAC I: LM: 13; SM: 12; II: LM: 24; SM: 22 | LM: 6.75 ± 1.32; SM: 6.02 ± 1.33 | NA | LM: 28.50 ± 11.01; SM: 26.40 ± 13.9 |
Ref. | Follow-up sample | Length of the myotomy, cm | Operative time, min | Myotomy length, cm | Follow-up time, mo | Clinical success | GERD, % | LESP, mmHg | HRM, mmHg | Post-ECK scores | Adverse events |
Familiari et al[15], 2016 | LM: 23 SM: 26 | LM: 13 SM: 8 | LM: 59.2 ± 16.7 SM: 47.7 ± 13.2 | ES: LM: 8.42 ± 2.13 SM: 3.87 ± 0.61 ST: LM: 2.49 ± 0.70 SM: 2.21 ± 0.41 TO: LM: 10.94 ± 2.11 SM: 6.04 ± 0.69 | 8 | LM: 100% SM: 100% | LM: 42.9% SM: 65% | LM: 17 ± 9.7 SM: 11.4 ± 6.5 | LM: 8.6 ± 4.9 SM: 5.9 ± 5.0 | LM: 0.5 ± 0.8 SM: 0.5 ± 0.8 | No |
Gao et al[16], 2017 | LM: 53 SM: 47 | LM: > 7 SM: ≤7 | LM: 63.13 ± 26.5 SM: 50.62 ± 20.02 | NA | 3,6,12 | LM: 96.2% SM: 93.6% | LM: 11.3% SM: 12.8% | LM: 16.51 ± 5.01 SM: 17.41 ± 3.69 | NA | LM: 0.98 ± 1.14 SM: 1.06 ± 1.42 | MB: LM: 0, SM: 0 MP: LM: 1; SM: 0 HS: LM: 10.19 ± 4.03 SM: 10.21 ± 3.78 |
Gong et al[17], 2016 | LM: 59 SM: 38 | LM: > 7 SM: ≤7 | LM: 68.5 ± 23.2 SM: 44.2 ± 16.3 | ES: LM: 8.5 ± 2.6 SM: 4.0 ± 0.9 ST: LM: 3.2 ± 1.4 SM: 2.1+0.3 TO: LM: 11.7 ± 2.4 SM: 6.1 ± 0.5 | NA | LM: 91.5% SM: 92.1% | LM: 18.6% SM: 15.8% | LM: 19.3 ± 8.5 SM: 16.7 ± 4.3 | NA | LM: 1.2 ± 1.2 SM: 1.0 ± 0.9 | MB: LM: 3; SM: 2 MP: LM: 1; SM: 0 HS: LM: 6.6 ± 1.1 SM: 6.4 ± 1.2 |
Gu et al[14], 2020 | LM: 48 SM: 46 | LM: 7-8 SM: 3-4 | LM: 45.6 ± 16.2 SM: 31.2 ± 15.3 | ES: LM: 10.14 ± 0.54 SM: 5.66 ± 0.14 | 1,3,6,12 | LM: 93.8% SM: 95.7% | LM: 22.9% SM: 15.2% | LM: 12.1 ± 3.9 SM: 11.8 ± 4.4 | LM: 9.7 ± 2.6 SM: 10.1 ± 2.4 | LM: 0.72 ± 0.42 SM: 0.76 ± 0.51 | HS: LM: 6: 5 ± 1.6 SM: 7.0 ± 0.9 |
Huang et al[13], 2020 | LM: 74 SM: 36 | LM > 7 SM≤ 7 | LM: 62.1 ± 25.2 SM: 46.6 ± 18.5 | ES: LM: 8.2 ± 2.7 SM: 4.0 ± 0.7 ST: LM: 3.2 ± 1.2 SM: 3.2 ± 1.2 TO: LM: 11.5 ± 3.1 SM: 6.0 ± 0.6 | 28.7 | LM: 91.9% SM: 94.4% | LM: 14.9% SM: 8.3% | LM: 13.3 ± 5.7 SM: 15.9 ± 3.2 | NA | LM: 1.6 ± 1.3 SM: 1.3 ± 1.2 | MB: LM: 3; SM: 2 MP: LM: 1; SM: 0 HS: LM: 9.3 ± 2.9 SM: 9.9 ± 2.4 |
Nabi et al[12], 2020 | LM: 37 SM: 34 | LM: ≥ 6 SM: ≤ 3 | LM: 72.43 ± 27.28 SM: 44.03 ± 13.78 | ES: LM: 7.97 ± 2.40 SM: 2.76 ± 0.41 ST: LM: 2.84 ± 0.63 SM: 2.70 ± 0.73 | 12 | LM: 96.97% SM: 93.55% | LM: 56.67%SM: 44.4% | NA | LM: 7.44 ± 4.30 SM: 8.60 ± 1.30 | LM: 0.818 ± 0.983 SM: 0.935 ± 0.929 | MB: LM: 17; SM: 12 HS: LM: 2.81 ± 0.70 SM: 2.82 ± 0.67 |
- Citation: Weng CY, He CH, Zhuang MY, Xu JL, Lyu B. Peroral endoscopic longer vs shorter esophageal myotomy for achalasia treatment: A systematic review and meta-analysis. World J Gastrointest Surg 2022; 14(3): 247-259
- URL: https://www.wjgnet.com/1948-9366/full/v14/i3/247.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i3.247